Abstract
We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecar...Continue Reading
References
Oct 1, 1992·Pathology·D H BarklaI P Hayward
Aug 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R Mangoo-KarimJ J Grantham
Oct 1, 1993·The American Journal of Physiology·K E Barrett
Mar 14, 2000·Archives of Medical Research·M MurakamiM Mori
Dec 5, 2002·The Journal of Clinical Investigation·Tonghui MaA S Verkman
Mar 15, 2003·The Journal of Biological Chemistry·Peter R WielingaPiet Borst
Apr 3, 2003·The Journal of Clinical Investigation·Michael Field
Apr 16, 2003·Molecular Pharmacology·Glen ReidPiet Borst
Aug 23, 2003·Circulation Research·Sergei D RybalkinJoseph A Beavo
Jan 24, 2004·Lancet·David A SackA K Siddique
Feb 6, 2004·Gastroenterology·Jay R ThiagarajahAlan S Verkman
Jul 28, 2004·The Journal of General Physiology·Chatchai MuanprasatA S Verkman
Apr 6, 2005·Trends in Pharmacological Sciences·Jay R Thiagarajah, A S Verkman
Aug 11, 2005·Current Drug Targets. Immune, Endocrine and Metabolic Disorders·G MeyerM Paulmichl
Feb 8, 2006·Annual Review of Physiology·Karnam S Murthy
Feb 24, 2006·Infection and Immunity·John K CraneMichael E Duffey
Apr 4, 2006·Cell Cycle·W C G van StaverenC Maenhaut
Jun 13, 2006·Cell and Tissue Research·William E Sweeney, Ellis D Avner
Sep 14, 2006·Pharmacological Reviews·Andrew T Bender, Joseph A Beavo
Feb 20, 2007·Circulation Research·Kenji Omori, Jun Kotera
Apr 17, 2007·Molecular Pharmacology·Buranee YangtharaA S Verkman
Nov 30, 2007·Cell·Chunying LiAnjaparavanda P Naren
Apr 4, 2008·Journal of the American Society of Nephrology : JASN·Baoxue YangA S Verkman
Jun 4, 2008·Seminars in Nephrology·Vicente E Torres
Citations
Jun 29, 2011·Journal of Medicinal Chemistry·David S SnyderA S Verkman
Nov 6, 2010·Assay and Drug Development Technologies·Stephen LinJane Staunton
Oct 8, 2009·Molecular Pharmacology·Lukmanee TradtrantipA S Verkman
May 9, 2013·Future Medicinal Chemistry·Chatchai Muanprasat, Varanuj Chatsudthipong
Dec 17, 2009·Current Opinion in Gastroenterology·Jayashree VenkatasubramanianMrinalini C Rao
Sep 17, 2015·Journal of the American Society of Nephrology : JASN·Hong YeVicente E Torres
Nov 20, 2009·Kidney International·Xiaofang WangVicente E Torres
Mar 12, 2010·Advances in Chronic Kidney Disease·Vicente E Torres
Sep 3, 2013·Current Opinion in Pharmacology·Jay R Thiagarajah, A S Verkman
Jan 16, 2019·Journal of Cellular Physiology·Talieh MalekshahabiReza Moghadasali
Dec 18, 2013·Journal of the American Society of Nephrology : JASN·Vicente E Torres, Peter C Harris
Jun 13, 2009·Journal of the American Society of Nephrology : JASN·Vicente E Torres
Dec 26, 2018·Clinical Kidney Journal·Roman-Ulrich Müller, Thomas Benzing
Apr 27, 2020·Cellular Signalling·Caroline R SussmanVicente E Torres